{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:23:57Z","timestamp":1792859037782,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T00:00:00Z","timestamp":1525910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s13318-018-0481-y","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T11:50:58Z","timestamp":1525953058000},"page":"693-706","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0494-5717","authenticated-orcid":false,"given":"Yoshiaki","family":"Ohtsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Susaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,10]]},"reference":[{"issue":"3","key":"481_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/095632029200300305","volume":"3","author":"LM Beauchamp","year":"1992","unstructured":"Beauchamp LM, Orr GF, de Miranda P, Bumette T, Krenitsky TA. Amino acid ester prodrugs of acyclovir. Antivir Chem Chemother. 1992;3(3):157\u201364.","journal-title":"Antivir Chem Chemother"},{"key":"481_CR2","unstructured":"GlaxoSmithKline. Product monograph for acyclovir oral suspension (zovirax). 2016. https:\/\/ca.gsk.com\/media\/592844\/zovirax.pdf . Accessed 17 Apr 2018."},{"issue":"12","key":"481_CR3","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1128\/AAC.39.12.2759","volume":"39","author":"J Soul-Lawton","year":"1995","unstructured":"Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother. 1995;39(12):2759\u201364.","journal-title":"Antimicrob Agents Chemother"},{"key":"481_CR4","unstructured":"GlaxoSmithKline. Product monograph for valacyclovir caplets (valtrex). 2015. https:\/\/ca.gsk.com\/media\/593038\/valtrex.pdf . Accessed 17 Apr 2018."},{"issue":"1","key":"481_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/cpt.3","volume":"97","author":"S James","year":"2015","unstructured":"James S, Larson K, Acosta E, Prichard M. Helicase-primase as a target of new therapies for herpes simplex virus infections. Clin Pharmacol Ther. 2015;97(1):66\u201378.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"481_CR6","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/jac\/dkq198","volume":"65","author":"K Chono","year":"2010","unstructured":"Chono K, Katsumata K, Kontani T, Kobayashi M, Sudo K, Yokota T, et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J Antimicrob Chemother. 2010;65(8):1733\u201341.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"481_CR7","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1128\/AAC.01803-12","volume":"57","author":"K Katsumata","year":"2013","unstructured":"Katsumata K, Chono K, Kato K, Ohtsu Y, Takakura S, Kontani T, et al. Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection. Antimicrob Agents Chemother. 2013;57(3):1339\u201346.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"481_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cpdd.108","volume":"3","author":"A Takada","year":"2014","unstructured":"Takada A, Katashima M, Kaibara A, Sawamoto T, Zhang W, Keirns J. Statistical analysis of amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes. Clin Pharmacol Drug Dev. 2014;3(5):365\u201370.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"481_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.dmpk.2016.05.005","volume":"31","author":"A Takada","year":"2016","unstructured":"Takada A, Katashima M, Kaibara A, Chono K, Katsumata K, Sawamoto T, et al. Integrative pharmacokinetic-pharmacodynamic modeling and simulation of amenamevir (ASP2151) for treatment of recurrent genital herpes. Drug Metab Pharmacokinet. 2016;31(4):323\u201332.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"11","key":"481_CR10","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/1346-8138.13948","volume":"44","author":"M Kawashima","year":"2017","unstructured":"Kawashima M, Nemoto O, Honda M, Watanabe D, Nakayama J, Imafuku S, et al. Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: a randomized, double-blind, valaciclovir-controlled phase 3 study. J Dermatol. 2017;44(11):1219\u201327.","journal-title":"J Dermatol"},{"issue":"2","key":"481_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10337-016-3236-4","volume":"80","author":"Y Ohtsu","year":"2017","unstructured":"Ohtsu Y, van Trigt R, Takama K, Groenendaal D, Takada A, Nakamura T, et al. Quantification of ASP2151 in human plasma and urine: a pitfall associated with supersaturation of analyte in urine. Chromatographia. 2017;80(2):217\u201327.","journal-title":"Chromatographia"},{"issue":"2","key":"481_CR12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0022-3565(25)32802-8","volume":"219","author":"P Miranda de","year":"1981","unstructured":"de Miranda P, Krasny HC, Page DA, Elion GB. The disposition of acyclovir in different species. J Pharmacol Exp Ther. 1981;219(2):309\u201315.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"481_CR13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0022-3565(25)32415-8","volume":"216","author":"HC Krasny","year":"1981","unstructured":"Krasny HC, de Miranda P, Blum MR, Elion GB. Pharmacokinetics and bioavailability of acyclovir in the dog. J Pharmacol Exp Ther. 1981;216(2):281\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1A","key":"481_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0002-9343(82)90071-7","volume":"73","author":"SS Good","year":"1982","unstructured":"Good SS, de Miranda P. Metabolic disposition of acyclovir in the guinea pig, rabbit, and monkey. Am J Med. 1982;73(1A):91\u20135.","journal-title":"Am J Med"},{"key":"481_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jchromb.2015.05.028","volume":"997","author":"Y Ohtsu","year":"2015","unstructured":"Ohtsu Y, Otsuka S, Nakamura T, Noguchi K. Regulated bioanalysis of conformers - A case study with ASP2151 in dog plasma and urine. J Chromatogr B. 2015;997:56\u201363.","journal-title":"J Chromatogr B"},{"key":"481_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/978-3-642-25240-2_33","volume-title":"Drug discovery and evaluation: safety and pharmacokinetic assays","author":"V Krone","year":"2013","unstructured":"Krone V. Absorption: in vivo tests (radiolabeled). In: Vogel HG, Maas J, Hock FJ, Mayer D, editors. Drug discovery and evaluation: safety and pharmacokinetic assays. Berlin: Springer; 2013. p. 799\u2013834."},{"key":"481_CR17","unstructured":"FDA. Draft redbook II toxicological principles for the safety assessment of direct food additives and color additives used in food, chapter V.B. metabolism and pharmacokinetic studies. 1993. https:\/\/www.fda.gov\/Food\/GuidanceRegulation\/GuidanceDocumentsRegulatoryInformation\/IngredientsAdditivesGRASPackaging\/ucm078717.htm . Accessed 17 Apr 2018."},{"key":"481_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1201\/9781420010084","volume-title":"Pharmacokinetics in drug discovery and development","author":"RD Schoenwald","year":"2002","unstructured":"Schoenwald RD. Basic principles. In: Schoenwald RD, editor. Pharmacokinetics in drug discovery and development. London: CRC Press; 2002. p. 3\u201330."},{"issue":"3","key":"481_CR19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1124\/dmd.105.007765","volume":"34","author":"J Ling","year":"2006","unstructured":"Ling J, Johnson KA, Miao Z, Rakhit A, Pantze MP, Hamilton M, et al. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos. 2006;34(3):420\u20136.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"481_CR20","first-page":"881","volume":"69","author":"Y Abe","year":"2014","unstructured":"Abe Y, Ota E, Endo T, Murakami M, Kobayashi M. Absorption, disposition, metabolism, and excretion of ritobegron (KUC-7483), a novel selective beta3-adrenoceptor agonist, in rats. Pharmazie. 2014;69(12):881\u20138.","journal-title":"Pharmazie"},{"issue":"3","key":"481_CR21","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3892\/etm.2012.627","volume":"4","author":"K Takeuchi","year":"2012","unstructured":"Takeuchi K, Shibata M, Kamiyama E, Umehara K. Expression levels of multidrug resistance-associated protein 4 (MRP4) in human leukemia and lymphoma cell lines, and the inhibitory effects of the MRP-specific inhibitor MK-571 on methotrexate distribution in rats. Exp Ther Med. 2012;4(3):524\u201332.","journal-title":"Exp Ther Med"},{"issue":"7","key":"481_CR22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1023\/A:1018943613122","volume":"10","author":"B Davies","year":"1993","unstructured":"Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093\u20135.","journal-title":"Pharm Res"},{"issue":"3","key":"481_CR23","first-page":"G365","volume":"258","author":"SK Sarin","year":"1990","unstructured":"Sarin SK, Sabba C, Groszmann RJ. Splanchnic and systemic hemodynamics in mice using a radioactive microsphere technique. Am J Physiol. 1990;258(3):G365\u20139.","journal-title":"Am J Physiol"},{"issue":"12","key":"481_CR24","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1007\/s12325-017-0642-4","volume":"34","author":"T Kusawake","year":"2017","unstructured":"Kusawake T, Keirns JJ, Kowalski D, den Adel M, Groenendaal-van de Meent D, Takada A, et al. Pharmacokinetics and safety of amenamevir in healthy subjects: analysis of four randomized phase 1 studies. Adv Ther. 2017;34(12):2625\u201337.","journal-title":"Adv Ther"},{"issue":"1","key":"481_CR25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0090-9556(25)08307-2","volume":"22","author":"TC Burnette","year":"1994","unstructured":"Burnette TC, de Miranda P. Metabolic disposition of the acyclovir prodrug valaciclovir in the rat. Drug Metab Dispos. 1994;22(1):60\u20134.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"481_CR26","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1124\/dmd.112.049239","volume":"41","author":"B Yang","year":"2013","unstructured":"Yang B, Smith DE. Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. Drug Metab Dispos. 2013;41(3):608\u201314.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"481_CR27","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1007\/s12325-017-0643-3","volume":"34","author":"T Kusawake","year":"2017","unstructured":"Kusawake T, Kowalski D, Takada A, Kato K, Katashima M, Keirns JJ, et al. The influence of hepatic and renal impairment on the pharmacokinetics of a treatment for herpes zoster, amenamevir (ASP2151): phase 1, open-label, single-dose, parallel-group studies. Adv Ther. 2017;34(12):2612\u201324.","journal-title":"Adv Ther"},{"issue":"11","key":"481_CR28","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1007\/s12325-017-0634-4","volume":"34","author":"T Kusawake","year":"2017","unstructured":"Kusawake T, den Adel M, Groenendaal-van de Meent D, Garcia-Hernandez A, Takada A, Kato K, et al. Pharmacokinetic evaluation of the interactions of amenamevir (ASP2151) with ketoconazole, rifampicin, midazolam, and warfarin in healthy adults. Adv Ther. 2017;34(11):2466\u201380.","journal-title":"Adv Ther"},{"key":"481_CR29","unstructured":"Maruho. Amenamevir package insert (Japanese). 2017. http:\/\/www.info.pmda.go.jp\/downfiles\/ph\/PDF\/730155_6250046F1028_1_02.pdf . Accessed 17 Apr 2018."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-018-0481-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0481-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0481-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T08:32:28Z","timestamp":1751617948000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-018-0481-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,10]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["481"],"URL":"https:\/\/doi.org\/10.1007\/s13318-018-0481-y","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,10]]},"assertion":[{"value":"10 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This research was funded by Astellas.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Y. Ohtsu and Y. Susaki are employees of Astellas. K. Noguchi was an employee of Astellas during the planning, experiment, and data interpretation of this research. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in, or financial conflict with, the subject matter or materials discussed in the manuscript other than those disclosed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted. All procedures performed in studies involving animals were approved by animal care and use committees where\u00a0the studies were conducted.\u00a0This article does not contain any studies with human participants performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}